-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, China Biopharmaceutical (01177.HK) issued an announcement. The results of a clinical study of the national Class 1 innovative drug TQ-A3334 (TLR7 agonist) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have been selected for the latest breakthrough summary (LBA) of the 2026 American Society for Liver Disease Research (AASLD) annual meeting (LBA), and will be announced in the form of an oral report; Chia Tai Tianqing and GlaxoSmithKline (GSK) strategic cooperation products Bepirovirsen (ASO) was selected for 2 oral presentations and 8 poster presentations (including 1 excellent poster).

Zhitongcaijing·10/14/2026 10:33:40
Listen to the news
Zhitong Finance App News, China Biopharmaceutical (01177.HK) issued an announcement. The results of a clinical study of the national Class 1 innovative drug TQ-A3334 (TLR7 agonist) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have been selected for the latest breakthrough summary (LBA) of the 2026 American Society for Liver Disease Research (AASLD) annual meeting (LBA), and will be announced in the form of an oral report; Chia Tai Tianqing and GlaxoSmithKline (GSK) strategic cooperation products Bepirovirsen (ASO) was selected for 2 oral presentations and 8 poster presentations (including 1 excellent poster).